A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Inclusion Criteria:
Exclusion Criteria:
Winston-Salem, North Carolina 27104, United States
Pittsburgh, Pennsylvania 15236, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires 1056, Argentina
CABA, Buenos Aires F.D. 1204, Argentina
Rosario, Santa Fe Province 2000, Argentina
Luoyang Shi, Henan 471003, China
Dalian, Liaoning 116033, China
Kamakura-shi, Kanagawa 247-0056, Japan
Ootaku, Tokyo 143-0015, Japan
Guadalajara, Jalisco 44670, Mexico
Mexico City, Mexico City 11650, Mexico
Culiacán, Sinaloa 80230, Mexico